Elevated fasting glucose is common in lung cancer patients undergoing 18F-FDG PET/CT: A brief report
More than half of lung cancer patients presenting for PET/CT had non-normal fasting glucose levels, even in the absence of traditional risk factors or known diabetes, underscoring the need for improved screening and management strategies in this population.
Authors
- Thomas Sartoretti (ORCID: https://orcid.org/0000-0002-4812-987X)
- Antonio Giulio Gennari (ORCID: https://orcid.org/0000-0003-2224-0083)
- Moritz Schwyzer (ORCID: https://orcid.org/0000-0002-9095-032X)
- Alessa Fischer (ORCID: https://orcid.org/0000-0003-4555-8334)
- J Walter
- Martin William Huellner (ORCID: https://orcid.org/0000-0002-4849-3292)
- Matthias Ernst (ORCID: https://orcid.org/0000-0002-6399-1177)
- Katharina Binz
- Michael Messerli (ORCID: https://orcid.org/0000-0001-7815-3048)
- G Hofer (ORCID: https://orcid.org/0000-0003-4843-1312)
- Bojan Bojanic
Institutions
- University of Zurich (CH)
- ETH Zurich (CH)
- University Hospital of Zurich (CH)
- Center for Pediatric Endocrinology Zurich (CH)
Publication Details
- Journal
- Metabolism Open
- Published
- 2025-10-15
- DOI
- https://doi.org/10.1016/j.metop.2025.100406
- Primary Topic
- Metabolism, Diabetes, and Cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00